tradingkey.logo
tradingkey.logo
Search

Precigen Inc

PGEN
Add to Watchlist
6.270USD
+0.330+5.56%
Close 07-31 16:00ETQuotes delayed by 15 min
2.24BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

+5.56%

5 Days

+16.11%

1 Month

+19.43%

6 Months

+39.64%

Year to Date

+50.00%

1 Year

+275.45%

Key Figures
5.940Open
6.280High
5.62MVolume
LossP/E TTM
29.53P/E Dynamic
--Dividend TTM
1.59%Turnover Ratio
5.940Prev. Close
5.920Low
23.39MTurnover
LossP/E Static
106.12P/B
0.00%Div Yield TTM
-152.89%ROA
5.46552wk High
1.27Volume Ratio
-126.23MNet Profit
353.91MShares
-1.2108EPS TTM
1.07Beta
-12418.40%ROE
1.28052wk Low
6.06%Amplitude
88.99%Gross Margin
2.24BMarket Cap
1.22Reward/Risk
4.99%Risk Rate

TradingKey Stock Score of Precigen Inc

Currency: USD Updated: 2026-07-31

Key Insights

Precigen Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 49 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.50.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Precigen Inc's Score

Industry at a Glance

Industry Ranking
49 / 155
Overall Ranking
109 / 4281
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

Precigen Inc Highlights

StrengthsRisks
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 55.57% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.68M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 9.68M.
Undervalued
The company’s latest PE is -5.18, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 270.08M shares, increasing 5.66% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 5.84M shares of this stock.

Analyst Rating

Based on 3 analysts
Buy
Current Rating
12.500
Target Price
+129.36%
Upside Space

Precigen Inc News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 3 analysts
Buy
Current Rating
12.500
Target Price
+99.36%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Precigen Inc
PGEN
3
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32

Indicators

Indicators
Sell(1)
Neutral(1)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
0.114
Buy
RSI(14)
69.807
Neutral
STOCH(KDJ)(9,3,3)
92.768
Overbought
ATR(14)
0.315
High Vlolatility
CCI(14)
219.807
Overbought
Williams %R
0.680
Overbought
TRIX(12,20)
0.381
Sell
StochRSI(14)
100.000
Buy
Moving Average
Sell(0)
Neutral(0)
Buy(6)
Indicators
Value
Direction
MA5
5.722
Buy
MA10
5.543
Buy
MA20
5.413
Buy
MA50
4.941
Buy
MA100
4.419
Buy
MA200
4.280
Buy

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Precigen Inc Info

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Ticker SymbolPGEN
CompanyPrecigen Inc
CEOSabzevari (Helen)
Websitehttps://precigen.com/

Shareholders

Shareholders
Shareholders
Proportion
Third Security, LLC
32.62%
Merck Serono SA
5.79%
Patient Capital Management, LLC
5.24%
Point72 Asset Management, L.P.
5.13%
William H. Miller III Living Trust
4.88%
Other
46.34%

FAQs

What is the current price of Precigen Inc (PGEN)?

The current price of Precigen Inc (PGEN) is 6.27.

What is the symbol of Precigen Inc?

The ticker symbol of Precigen Inc is PGEN.

What is the 52-week high of Precigen Inc?

The 52-week high of Precigen Inc is 5.46.

What is the 52-week low of Precigen Inc?

The 52-week low of Precigen Inc is 1.28.

What is the market capitalization of Precigen Inc?

The market capitalization of Precigen Inc is 2.22B.

Is Precigen Inc (PGEN) currently rated as Buy, Hold, or Sell?

According to analysts, Precigen Inc (PGEN) has an overall rating of Buy, with a price target of 12.50.

What is the Earnings Per Share (EPS TTM) of Precigen Inc (PGEN)?

The Earnings Per Share (EPS TTM) of Precigen Inc (PGEN) is -1.37.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.